Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry—Communication from the ISTH SSC for Women’s Health

Rezan Abdul Kadir1,2 | Takao Kobayashi3 | Toshiaki Iba4 | Offer Erez5 | Jecko Thachil6 | Sajida Kazi7 | Ann Kinga Malinowski8 | Maha Othman9,10

© 2020 International Society on Thrombosis and Haemostasis

Manuscript handled by: Jean Connors
Final decision: Jean Connor, 18 August 2020

Abstract

Background: Novel coronavirus (SARS-CoV-2), which causes COVID-19, has thus far affected more than 15 million individuals, resulting in more than 600,000 deaths worldwide, and the number continues to rise. In a large systematic review and meta-analysis of the literature including 2567 pregnant women, 7% required intensive care admission, with a maternal mortality ~1% and perinatal mortality below 1%. There has been a rapid increase in publications on COVID-19–associated coagulopathy, including disseminated intravascular coagulopathy and venous thromboembolism, in the non-pregnant population, but very few reports of COVID-19 coagulopathy during pregnancy; leaving us with no guidance for care of this specific population.

Methods: This is a collaborative effort conducted by a group of experts that was reviewed, critiqued, and approved by the International Society on Thrombosis and Haemostasis Subcommittee for Women’s Health Issues in Thrombosis and Hemostasis. A structured literature search was conducted, and the quality of current and emerging evidence was evaluated. Based on the published studies in the non-pregnant and pregnant population with a moderate to high risk of bias as assessed by Newcastle-Ottawa scale and acknowledging the absence of data from randomized clinical trials for management of pregnant women infected with SARS-CoV-2, a consensus in support of a guidance document for COVID-19 coagulopathy in pregnancy was identified.

Results and Conclusions: Specific hemostatic issues during pregnancy were highlighted, and preliminary recommendations to assist in the care of COVID-19–affected pregnant women with coagulopathy or thrombotic complications were developed. An international registry to gather data to support the management of COVID-19 and associated coagulopathy in pregnancy was established.

Keywords

COVID-19, COVID-19 pregnancy registry, pregnancy and coagulopathy, pregnancy and venous thromboembolism, thromboprophylaxis in pregnancy
1 | INTRODUCTION

The novel coronavirus (SARS-CoV-2), previously known as 2019-nCoV, which causes COVID-19, has thus far affected more than 15 million individuals, resulting in more than 600 000 deaths worldwide, and the number continues to rise. Most patients have mild symptoms and fully recover. However, the infection can be severe in some individuals, especially those with comorbidities, and may progress to pneumonia, respiratory compromise, and multi-organ failure, with a significant impact on hospital and intensive care (ICU) admissions and overall mortality.

Pregnancy, by virtue of its inherent physiological adaptations, would be expected to increase the risk of morbidity associated with COVID-19, particularly owing to: (a) a relatively immunocompromised state secondary to alterations within the body's cell-mediated immune response and inflammatory mechanisms, (b) alteration of pulmonary function, and (c) a hypercoagulable state established in preparation for prevention of postpartum hemorrhage and restoration of hemostasis following birth. These changes indeed hamper interpretation of coagulation-related laboratory data in association with COVID-19. In contrast to previous coronavirus outbreaks responsible for Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) during which pregnant women were noted to experience high rates of severe morbidity and mortality, thus far the COVID-19 infection overall does not appear to affect pregnant women more severely than the general population. However, severe disease does occur with potential for evolution of coagulopathy, multi-organ failure, and even maternal death.

The purpose of this report is to: (a) examine the current evidence of COVID-19 outcomes in pregnancy, (b) highlight the specific pregnancy-related hemostatic issues, (c) provide recommendations to guide care of COVID-19-affected pregnant women with respect to coagulopathy, and (d) introduce an international registry to systematically analyze the occurrence and impact of coagulopathy in women with COVID-19 during pregnancy and the post partum period.

2 | METHODS, SEARCH STRATEGY, AND RISK OF BIAS ASSESSMENT

This is a collaborative effort conducted by a group of experts, which was reviewed, critiqued, and approved by the International Society on Thrombosis and Haemostasis (ISTH) Subcommittee for Women's Health Issues in Thrombosis and Hemostasis.

In a virtual meeting facilitated by the ISTH, the authors discussed and identified an unmet need for guidance regarding management of COVID-19 coagulopathy in pregnancy. All recognized that the ISTH published guidance did not address pregnancy-specific issues. The authors thus planned to work together to develop preliminary recommendations based on expert opinion, given the paucity of evidence in the literature, together with developing an international registry to facilitate a global concerted effort to gain more insight into the issues of coagulopathy and thrombosis in the context of COVID-19 in pregnancy. Consensus was obtained between all authors, as well as the co-chairs of ISTH Women's Health Issues in Thrombosis and Hemostasis Scientific and Standardization Committee (SSC) that the main questions to be addressed in the document would relate to guidance regarding cut-off values for various lab tests that help diagnose coagulopathies in association with COVID-19, as well as guidance regarding management of coagulopathy and venous thromboembolism (VTE) thromboprophylaxis in COVID-19-affected pregnancies.

A structured literature search was conducted using MEDLINE (1946 to 16 July 2020), EMBASE (1947 to 16 July 2020), and EPUB Ahead of Print & Other Non-Indexed Citations (inception to 16 July 2020). The search was conducted using the medical subject headings (MeSH) terms: COVID19, SARS COV, and coagulopathy, thrombosis, venous thromboembolism, coagulation disorders, and anticoagulation. For pregnancy affected by COVID-19 illness and coagulopathy, the MeSH terms included all the above terms and pregnancy. The search was limited to publications in the English language. Articles were included if they represented a randomized controlled trial, cohort study, case-control study, or case series of at least 10 non-pregnant patients with COVID-19 infection. Given limited data, for pregnancy, case series with fewer than 10 participants and case-reports were included. The Risk of Bias for individual studies was assessed using the Newcastle-Ottawa scale (NOS). The maximum number of stars a study could be awarded was 8 and studies receiving more than 6, 4–6, and <4 stars were considered to be at low, intermediate, and high risk of bias, respectively. Studies with high risk of bias were excluded.

Figure S1 in supporting information summarizes our search strategy and approach.

3 | COVID-19 AND PREGNANCY OUTCOMES

Following removal of duplicates, 669 papers were identified for COVID-19 and pregnancy outcomes, 184 of which were selected...
for full text review. Ten retrospective cohort studies and one prospective cohort study met the inclusion criteria and were retained (Figure S1A). Reported outcomes included: admission, pregnancy complication, death, thromboembolism, or coagulopathy. Follow-up was at least to the end of the admission. Outcome data were available for at least 90% of patients. The risk of bias assessment according to the NOS is summarized in Table 1. The support for the assessments for individual studies is available in Table S1 in supporting information.

The pregnancy data remain conflicting and will likely continue to be updated as more studies of affected pregnancies become available. Several publications have presented findings of COVID-19 in pregnancy, including a recent systematic review and meta-analysis of 17 studies including 2567 pregnancies. Increased maternal mortality and poor obstetric outcomes, including the risk of preterm birth, intrauterine growth restriction, and perinatal death have been demonstrated in association with other coronaviruses such as SARS and MERS. In COVID-19 infection, case fatality rate in pregnant women appears to be comparable to non-pregnant women of reproductive age. However, the propensity for severe disease in pregnancy does exist, especially with advanced gestation, having been noted in 8% of COVID-19–affected pregnant women in a series from China, and in 9% to 10% in reports from New York, with 4% listed as critical.

According to data from the Centers for Disease Control and Prevention (CDC) in the United States, among women aged 15 to 44 years with COVID-19, pregnant women were hospitalized at a higher rate compared to non-pregnant women (31.5% versus 5.8%), pregnant women were also more likely to be admitted to the ICU and to receive mechanical ventilation. The United Kingdom’s Obstetric Surveillance System (UKOSS) data are consistent with these estimates, describing pregnant women admitted to hospital with COVID-19 infection in 4.9/1000 maternities, with 9% progressing to the need for critical care support, and with maternal mortality in 7.5% of those requiring critical care. In a series of 64 COVID-19–affected pregnant women who were hospitalized in 12 institutions in the United States, 69% and 31% had severe and critical disease, respectively, with admission at a mean of 30 weeks’ gestation. All those with critical disease were treated with prophylactic or therapeutic anticoagulation throughout hospital admission. Intubation, when required, was typically needed on day nine with no maternal deaths. Preterm birth occurred in 75% (15/20) of women with critical disease. No stillbirths or neonatal deaths were recorded. Likewise, in a report from Wuhan, China, including 118 COVID-19–affected pregnancies, fever and cough were the most frequently observed symptoms, seen in more than 70%. Lymphopenia was observed in 44%, while severe illness was noted in 8%. Of the 118 pregnancies, 68 (58%) have been delivered, 93% by cesarean delivery, with the sole indication of COVID-19 concerns noted as a reason for the procedure in 61%. Preterm birth was reported in 21%, eight of which were iatrogenic. Increased risks of iatrogenic preterm births and cesarean deliveries were also shown in the recent systematic review of 2567 women with COVID-19 in pregnancy. Contrasting evidence exists with respect to the potential for vertical transmission. A rate of neonatal SARS-CoV-2 positivity is estimated between 1% and 2%. Suspected perinatal SARS-CoV-2 infection, with evidence of immunoglobulin (Ig)M and IgG antibodies in neonates, has been reported. Similarly, positive neonatal nasopharyngeal samples from infected mothers together with evidence of placental inflammation and fibrin deposition were also described. Thus, vertical transmission is possible, though it appears to be rare. Caution is warranted with respect to interpretation of test results as potential contamination from maternal secretions or tissues must be excluded.

4 | COVID-19 COAGULOPATHIES IN THE NON-PREGNANT PATIENTS

After duplicates were excluded, the search strategy yielded 1257 records, of which 371 underwent full-text review. In total, 24 reports met the inclusion criteria (Figure S1B). Reported outcomes included death, thromboembolism, or coagulopathy and follow-up was at least to the end of the admission. Outcome data were available for at least 90% of patients. The risk of bias assessment, according to the NOS, is summarized in Table 1 and support for the judgements for individual studies is available in the Table S1. Cases of disseminated intravascular coagulopathy (DIC) in the non-pregnant population had pro-coagulant DIC, characterized by high fibrinogen and D-dimer concentrations and a prothrombotic presentation.

ISTH interim guidance and Expert Opinion for recognition and management of coagulopathy in non-pregnant COVID-19 patients, alongside guidance for VTE management in hospitalized patients have now been published. The key points are summarized in Table 2. It is to be noted that none of the three guidance documents have addressed pregnancy-specific issues, a gap the current document aims to address.

5 | COVID-19 COAGULOPATHIES IN PREGNANCY

Based on our search, only four publications relevant to COVID-19 coagulopathy in pregnancy were identified. All were case reports. Coagulopathy or thrombotic complications were reported in these studies. Outcome data were available for at least 90% of patients. All studies were assigned moderate risk of bias with the risk of bias assessment for the reports, according to the NOS, summarized in Table 1. The support for our judgements is available in Table S1.

The first study is a single report of two cases of COVID-19–related coagulopathy observed in the third trimester of pregnancy. This report documents rapidly progressive thrombocytopenia (nadir 78 × 10^9/L in case 1 and 54 × 10^9/L in case 2), activated partial thromboplastin time (APTT) prolongation (peak of 41.2 and 60 seconds in the two cases, respectively), low fibrinogen ( nadir 2.2 g/L in case 1 and 0.8 g/L in case 2), and D-dimer elevation (17x and 12x the upper range of normal for pregnancy in the two cases,
| Author, country | Single vs multicenter | Design | Number of patients/pregnancies | Inclusion criteria | Risk of bias assessment (NOS) | Risk of bias: 1-3: high 4-6: moderate 7-8: low |
|----------------|----------------------|--------|-------------------------------|-------------------|-----------------------------|-----------------------------------------------|
| COVID-19 (Pregnant) |                       |        |                               |                   |                             |                                               |
| National cohort study using the UK Obstetric Surveillance System (UKOSS) | Multicenter | Prospective Cohort | 427 | COVID-19 | *** | - | ** | 5 | Moderate |
| Ferrazzi | Single | Retrospective cohort | 42 | COVID-19 | *** | - | *** | 6 | Moderate |
| Ferrazzi | Italy | Unites States |  | | | | | |
| Breslin | Single | Retrospective cohort | 43 | COVID-19 | *** | ★ | *** | 7 | Low |
| Qiancheng | Single | Retrospective cohort | 24 | COVID-19 | *** | ★ | *** | 7 | Low |
| Pierce-Williams | Multicenter | Retrospective cohort | 64 | COVID-19 | *** | ★ | *** | 7 | Low |
| Yan | Multicenter | Retrospective cohort | 116 | COVID-19 | *** | ★ | *** | 7 | Low |
| Collin | Multicenter | Retrospective cohort | 53 | COVID-19 | *** | ★ | *** | 7 | Low |
| Ellington | Multicenter | Retrospective cohort | 91 412 | COVID-19 | *** | - | *** | 6 | Moderate |
| Pereira | Single | Retrospective cohort | 60 | COVID-19 | *** | - | ** | 5 | Moderate |
| Sentilhes | Single | Retrospective cohort | 54 | COVID-19 | *** | - | ** | 5 | Moderate |
| Nayak | Single | Retrospective cohort | 977 | COVID-19 | *** | ★ | *** | 7 | Low |
| COVID-19 coagulopathy (non-pregnant) |                       |        |                               |                   |                             |                                               |
| Tang | Single | Prospective cohort | 183 | COVID-19 | *** | - | ** | 5 | Moderate |
| Klok | Multicenter | Prospective cohort | 184 | COVID-19 | ** | - | ** | 4 | Moderate |
| Middeldorp | Single | Prospective cohort | 198 | COVID-19 | *** | ★ | ** | 6 | Moderate |

(Continues)
| Author, country  | Single vs multicenter | Design                        | Number of patients/ pregnancies | Inclusion criteria | Risk of bias assessment (NOS) | Total/8 | Risk of bias: 1-3: high 4-6: moderate 7-8: low |
|-----------------|-----------------------|-------------------------------|--------------------------------|--------------------|------------------------------|---------|-------------------------------------------------|
| Tang 6, 7 China | Single                | Retrospective cohort          | 449                            | COVID-19           | ★                            | 4       | Moderate                                        |
| Fogarty 6, 8     | Single                | Retrospective cohort          | 83                             | COVID-19           | ★★                           | 6       | Moderate                                        |
| Panigada 6, 9    | Single                | Prospective cohort            | 24                             | COVID-19           | ★                            | 2       | High                                           |
| Litjos 6, 10     | Single                | Retrospective cohort          | 26                             | COVID-19           | ★                            | 2       | High                                           |
| Cui 6, 11        | Single                | Retrospective cohort          | 81                             | COVID-19           | ★                            | 3       | High                                           |
| Helms 6, 12      | Single                | Retrospective cohort          | 150                            | COVID-19           | ★★                           | 6       | Moderate                                        |
| Ranucci 7, 13    | Single                | Retrospective cohort          | 16                             | COVID-19           | ★                            | 3       | High                                           |
| Poissy 6, 14      | Single                | Retrospective cohort          | 107                            | COVID-19           | ★                            | 3       | High                                           |
| Spiezia 6, 15     | Single                | Prospective cohort            | 22                             | COVID-19           | ★★                           | 3       | High                                           |
| Lodigiani 6, 16  | Single                | Retrospective cohort          | 388                            | COVID-19           | ★★                           | 5       | Moderate                                        |
| Stoneham 6, 17    | Single                | Retrospective cohort          | 274                            | COVID-19           | ★                            | 7       | Low                                            |
| Longchamp 6, 18   | Single                | Retrospective cohort          | 25                             | COVID-19           | ★                            | 4       | Moderate                                        |
| Ren 6, 19 China   | Multicenter           | Retrospective cohort          | 48                             | COVID-19           | ★                            | 4       | Moderate                                        |
| Al-Samkari 6, 20  | Multicenter           | Retrospective cohort          | 400                            | COVID-19           | ★                            | 4       | Moderate                                        |
| Hippensteel 6, 21 | Single                | Retrospective cohort          | 106                            | COVID-19           | ★                            | 4       | Moderate                                        |
| Fraisse 6, 22     | Single                | Retrospective cohort          | 92                             | COVID-19           | ★                            | 4       | Moderate                                        |
| Santoliquido 6, 23| Single                | Retrospective cohort          | 84                             | COVID-19           | ★                            | 4       | Moderate                                        |

(Continues)
| Author, country | Single vs multicenter | Design               | Number of patients/pregnancies | Inclusion criteria | Risk of bias assessment (NOS) | Risk of bias: 1-3: high 4-6: moderate 7-8: low |
|----------------|-----------------------|----------------------|-------------------------------|-------------------|-----------------------------|---------------------------------------------|
| Rieder³³ Germany | Single                | Prospective cohort   | 190                           | COVID-19           | *** | * | *** | 7 | Low |
| Pavoni³⁴ Italy   | Single                | Retrospective cohort | 40                            | COVID-19           | *** | - | *** | 6 | Moderate |
| Nougier³⁵ France | Single                | Retrospective cohort | 78                            | COVID-19           | *** | * | *** | 7 | Low |
| Vlachodimitropoulou³³ Canada | Single | Case report           | 2                             |                   | * | ** | ** | * | 6 | Moderate |
| Martinelli²⁷ Italy | Single               | Case report           | 1                             |                   | * | * | * | * | 4 | Moderate |
| Mohammad²⁹ Iran  | Single                | Case report           | 1                             |                   | * | * | * | * | 4 | Moderate |
| Ahmed³⁰ United Kingdom | Single               | Case Report           | 1                             |                   | * | ** | ** | * | 6 | Moderate |

Abbreviation: NOS, Newcastle Ottawa scale.

*The number of stars is the standard assessment method used in this scale. The maximum number of stars a study could be awarded was 8 and studies receiving more than 6, 4–6, and <4 stars were considered to be at low, intermediate, and high risk of bias, respectively.
Three other case reports highlight the prothrombotic risk of COVID-19, in young pregnant women admitted with COVID-19 infection, without personal or family history of thrombosis.\(^{27-29}\) The first of these cases highlighted the course of a woman with elevated body mass index (BMI) who developed a segmental pulmonary embolism during the course of her COVID-19 illness,\(^{27}\) the second described a woman who presented with abdominal pain and vomiting, was found to be positive for SARS-CoV-2, and was eventually diagnosed with ovarian vein thrombosis.\(^{29}\) The third case report presented COVID-19 illness during pregnancy in a young woman with a BMI of 35 kg/m\(^2\) and poorly controlled Type 2 diabetes mellitus, which was complicated by basilar artery stroke, pulmonary embolism, and maternal mortality.\(^{28}\) All three patients required oxygen support and either non-invasive or invasive ventilation. Alongside obesity, a comorbidity common to both these cases, which was previously reported to increase the risk of severity of COVID-19,\(^{27}\) diabetes mellitus has also been implicated as a risk factor for development of severe COVID-19 illness and increased mortality.\(^{31,32}\)

### TABLE 2

| Hemostatic parameters in COVID-19 coagulopathies in non-pregnant women. A summary of published studies, ISTH guidance, and expert opinion for recognition and management in hospitalized patients |
|---------------------------------|---------------------------------|---------------------------------|
| **Normal values**               | **Pathological alterations in COVID-19**                                      | **ISTH Interim Guidance and Expert Opinion\(^{24-26}\)** |
| PT                              | Prolonged in 50% of non-survivors but only 7% of survivors (P < .0001)\(^{30}\) | • Measure in all patients with COVID-19 to identify and monitor coagulopathy |
| APTT                            | No significant changes at admission but significant prolongation of PT and not APTT at day 4 \(^{47}\) | • Admit if PT is prolonged |
| D-dimer                         | 0–0.5 µg/mL is associated with severe disease compared \(^{86}\) | • Monitor PT at least twice daily in all hospital admitted patients |
|                                 | Significantly elevated in critically ill patients compared to non \(^{87}\) | • In bleeding patients (rare in COVID-19), maintain PT ratio < 1.5 |
| Platelet                        | <100 × 10\(^7\)/L is associated with severe disease or in critically ill \(^{30,87,88}\) | • Measure in all patients with COVID-19 to identify and monitor coagulopathy |
|                                 | Increased platelet counts in severe cases due to cytokine storm \(^{43,89}\) | • Admit if markedly raised |
|                                 | Increased > 4 upon admission with significant difference between survivors and non-survivors \(^{80,87}\) | • Monitor at least twice daily in all hospital admitted patients |
| Fibrinogen                      | 2–4 g/L | • In bleeding patients (rare in COVID-19), maintain >2.0 g/L |
| FDPs                            | Increased \(^{80,80}\) | • Prophylactic LMWH in all patients (including non-critically ill) who require hospital admission, in the absence of contraindications (active bleeding and platelet count <25 × 10\(^9\)/L). Abnormal PT or APTT not a contraindication) |
| Lupus Anticoagulant             | Positive \(^{71}\) | • Consider VTE in the setting of rapid respiratory deterioration and/or high D-dimer |
| VTE risk                        | Number of patients admitted to ICU | • Consider CT angiography or ultrasound of the venous system of the lower extremities to evaluate presence/absence of VTE |
|                                 | 184\(^{64,91}\) | Number (percentage) of patient developed VTE |
|                                 | 75\(^{55,66}\) | 28 (27%) |
|                                 | 150\(^{71}\) | 35 (47%) |
|                                 | 48\(^{75}\) | 64 (42%) |
|                                 | 8 (16.7%) |
| Laboratory parameter | Third trimester of pregnancy | Non-pregnant women | Possible alterations in pregnancy with COVID-19 | Potential prognostic markers | Levels reported in severe COVID-19 outside pregnancy$^a$ |
|-----------------------|-----------------------------|--------------------|-----------------------------------------------|-----------------------------|--------------------------------------------------|
| PT                   | 8.5–11.0 seconds            | 16.0 seconds       | • COVID coagulopathy Or DIC                   | Yes                         | 3 s extension >6 in 47.6% of non-survivors with DIC compared to 3 in survivors |
| APTT                 | 25.5–42.5 seconds          | 27.0–37.0 seconds  | • COVID coagulopathy Or DIC                   | Yes                         | 5 s extension                                    |
| D-dimer              | 0.16–1.7 μg/mL             |                    | • COVID coagulopathy Or DIC                   | Yes (severe disease and in hospital mortality Cut off: 2.0 μg/mL) | 2.12 in non survivors Vs 0.61 in survivors >3 in 86% non-survivors with DIC |
| Platelet count Mean (range) | Third trimester Delivery PP | 225 (57–505) x 10^9/L 217 (63–552) x 10^9/L 264 (91–575) x 10^9/L 273 (111–999) x 10^9/L | • COVID coagulopathy Or DIC • PPH • Cytokines induced | Yes Thrombocytopenia (severe disease + mortality) | <100 in 33% of non-survivors <50 in 24% non-survivors with DIC |
| Fib                  | 2.48–5.06 g/L              | 2.5–4.0 g/L        | • COVID coagulopathy Or DIC                   | Yes                         | 5.16 in non survivors vs 4.5 in survivors (non significant difference) <1 in 29% non-survivors with DIC |
| FDPs                 | <15 μg/mL                  | 3.09 ± 1.96 μg/mL  | • COVID coagulopathy Or DIC                   | 7.6 in non survivors vs 4.0 in survivors |

Note: Please note this table is a guide. Age and ethnic variations exist and need to be considered. References: 30,34,39,40,43,89.

Abbreviations: APTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulopathy; FDPs, fibrin degradation products; Fib, fibrinogen; PP, post partum; PT, prothrombin time; VTE, venous thromboembolism.

$^a$Reference: 30; 71% of non-survivors developed DIC (ISTH DIC score of ≥5) vs 0.6% of survivors.
5.1 | Pregnancy-specific guidance

Based on our understanding of the specific key physiological alterations associated with pregnancy (Table 3) and the current available evidence on COVID-19 in pregnancy as well as COVID-19 coagulopathies, we highlight specific issues that require careful considerations in pregnancy when interpreting the hemostatic parameters and cut-off values suggested for monitoring and management of COVID-19 coagulopathy in the non-pregnant population. We also provide preliminary recommendations to guide laboratory assessments and clinical management of COVID-19 coagulopathy in pregnant patients. Due to a low level of certainty of the evidence, and recognizing that future research may alter these recommendations, we have used the word “suggest” rather than “recommend.”

5.1.1 | Prothrombin time (PT) and APTT

We suggest the use of PT ratio and APTT ratio\(^\text{32}\) during pregnancy with a ratio ≥1.5 as cut-off for coagulopathy, rather than reliance on prolonged PT and APTT measured in seconds.

**Evidence and rationale**
Due to the increase in coagulation factors toward term, PT and APTT are shortened in pregnancy, especially during the third trimester. Alongside gestational age-specific ranges for PT and APTT based on samples from 1130 pregnant women, Liu et al reported median PT and APTT levels at 36 weeks of 9.60 and 31.00 seconds, respectively.\(^\text{34}\)

5.1.2 | Fibrinogen

We suggest an individualized assessment of fibrinogen activity levels, with specific attention to hypofibrinogenemia in the obstetric setting. Further studies are required to confirm fibrinogen thresholds and their prognostic utility in the setting of COVID-19 in pregnancy.

**Evidence and rationale**
Fibrinogen increases in pregnancy, with levels reported to be as high as 3.7 to 6.2 g/L during the third trimester.\(^\text{25}\) In one study the median level at 36 weeks of pregnancy was noted to be 3.86 g/L.\(^\text{34}\) Fibrinogen < 3 g/L had an assigned weight of 25 in the pregnancy-specific DIC score.\(^\text{36}\) Furthermore, during the course of a post partum hemorrhage (PPH), a study of 128 women demonstrated that fibrinogen ≤ 2 g/L had a positive predictive value of 100% for severe PPH.\(^\text{37}\) Tang et al reported no significant change in the fibrinogen level between COVID-19 survivors and non-survivors on admission.\(^\text{30}\) By late hospitalization, however, the fibrinogen level was significantly lower in non-survivors. Thus, elevated fibrinogen level is likely to be a reflection of the inflammatory state, but if the patient is deteriorating and developing coagulopathy, low levels can be seen. Hypofibrinogenemia (compared to normal pregnancy levels) was seen in the two case reports of acute coagulopathy with COVID-19 in pregnancy,\(^\text{8}\) one patient had a severe PPH requiring blood products, the other had fibrinogen concentrate pre-operatively and did not experience excessive bleeding.

5.1.3 | Platelet count

We suggest using the clinically relevant platelet count threshold of ≤100 \(\times 10^9/\text{L}\) to define thrombocytopenia during pregnancy, as would be the case for pregnancies not affected by COVID-19. A platelet count that is critical for bleeding risk in pregnancy varies according the clinical situation; while a threshold of 30 \(\times 10^9/\text{L}\) is used during pregnancy, a minimum platelet count of 50 \(\times 10^9/\text{L}\) is required for delivery.

**Evidence and rationale**
There is a drop in platelet count in pregnancy and gestational thrombocytopenia affects 5% to 11% of pregnant women in the second and third trimesters.\(^\text{38}\) Medians and ranges of platelet counts in various trimesters compared to the non-pregnant state have been reported.\(^\text{35,39}\) While there is no evidence in the literature regarding platelet count thresholds specific to COVID-19–affected pregnancies, pragmatic guidance regarding this parameter is included in the interest of inclusivity.

5.1.4 | D-dimer

We suggest markedly elevated D-dimers several-fold above the upper range of normal for pregnancy (noting that a level of 2 \(\mu\text{g/mL}\) can still be seen in normal pregnancy) should be considered as indicative of coagulopathy.

**Evidence and rationale**
D-dimer levels increase progressively in pregnancy and peak in the third trimester. One study reported levels of: 0.11 to 0.40 \(\mu\text{g/mL}\), 0.14 to 0.75 \(\mu\text{g/mL}\), and 0.16 to 1.3 \(\mu\text{g/mL}\) in first, second, and third trimester, respectively.\(^\text{35}\) While in another study 1.7 \(\mu\text{g/mL}\) was reported as the upper limit in the third trimester.\(^\text{35}\) Yet another report found a D-dimer > 0.5 \(\mu\text{g/mL}\) in 99% of women during the third trimester.\(^\text{41}\) In the recent study by Tang et al, an elevated D-dimer was one of the predictors of mortality in the non-pregnant population with COVID-19, with levels of 2.12 \(\mu\text{g/mL}\) (range 0.77–5.27 \(\mu\text{g/mL}\)) in COVID-19 non-survivors compared to 0.61 \(\mu\text{g/mL}\) (range 0.35–1.29 \(\mu\text{g/mL}\)) in survivors.\(^\text{30}\) A level of 2 \(\mu\text{g/mL}\) can still be within the normal range for pregnant women and the significance of mild to moderate D-dimer elevation in pregnancy remains unknown. While further data are required before a threshold for pregnant women can be suggested, in the interim given clear evidence of association between D-dimer elevation and COVID-19 coagulopathy/mortality in the non-pregnant state, significant D-dimer elevations should raise suspicion of potential deterioration and should be evaluated carefully.
5.1.5 | Fibrin-degradation products (FDPs)

We suggest that any elevated levels of FDP should be taken as an early pathological sign, especially when associated with abnormalities of other parameters of coagulopathy.

Evidence and rationale
FDP levels were elevated in non-pregnant non-survivors of COVID-19. FDP levels do not seem to undergo significant change during normal pregnancy, but increase markedly during labor and the first week after normal delivery. Significantly elevated levels are observed in association with complicated pregnancies, such as abruptio placentae, eclampsia, intrauterine fetal death, and PPH. The reported range of FDPs in association with COVID-19 outside pregnancy is 4.0 – 15.0 μg/mL, with an average of 7 μg/mL.

5.1.6 | DIC

We suggest the use of pregnancy-modified ISTH DIC score, to differentiate overt and non-overt DIC during pregnancy.

Evidence and rationale
Scoring systems for diagnosis of DIC have been developed by the Japanese Association for Acute Medicine (JAAM) and ISTH. The pregnancy-modified ISTH score was calculated based on a population of 24,646 pregnancies without and 87 with DIC (n = 24,693), had a 96% specificity, and in an independent study attained a sensitivity of 78% and a specificity of 97%. This modified score has proven useful for the identification of patients at risk for obstetrical hemorrhage requiring blood product transfusion and can be applied in COVID-19–affected pregnancies.

5.1.7 | Hypercoagulability and VTE risk

1. Given the possible increase in coagulopathy and VTE risk with COVID-19, as for the non-pregnant population, weight-adjusted VTE prophylaxis with low molecular weight heparin (LMWH) should be considered in all pregnant and post partum women admitted to hospital with COVID-19 infection in the absence of active bleeding and with a platelet count above 30 x 10^9/L, provided urgent delivery is not anticipated or timing is beyond 24 hours post partum. If potential need for emergent delivery in a critically ill woman is likely, and during the immediate post partum period, thromboprophylaxis should be considered individually, with input from a multidisciplinary team including specialists of maternal medicine and thrombosis and hemostasis.

2. Prolonged PT and APTT should not be considered as a contraindication for thrombo-prophylaxis.

3. If anticoagulation is contraindicated in admitted patients, mechanical prophylaxis (intermittent pneumatic compression) should be instituted.

4. In preparation for discharge, a careful and individualized VTE risk assessment should be performed taking into consideration other VTE risk factors to plan duration of LMWH after discharge:
   - For those with a less severe condition and a short period of hospitalization, which did not result in delivery, 10 to 14 days of LMWH may be appropriate.
   - For those with a severe disease, with very high D-dimer levels, particularly in the third trimester, this may mean continuation of LMWH throughout the rest of pregnancy and post partum.
   - For post partum women, the duration of thromboprophylaxis may vary from 2 to 6 weeks, depending on other risk factors, mode of delivery, severity of COVID-19 infection, and duration of admission.
   - Dose, duration, and type of anticoagulation should be determined individually for critically ill patients and those with complex medical conditions during hospitalization and after discharge, in collaboration with experts in critical care, thrombosis, and hemostasis, and maternal-fetal medicine.

5. For the majority of women with mild-moderate disease who are managed at home, VTE risk assessment should be performed carefully. For those who are low risk, hydration, appropriate nutrition, mobilization, and control of pyrexia should be encouraged. Use of anti-embolic stockings at home may be encouraged. LMWH thromboprophylaxis should be considered in the presence of immobility, high fever, dehydration, or additional maternal risk factors for VTE, which are highlighted in the Royal College of Obstetricians and Gynaecologists (RCOG) guideline.

Evidence and rationale
Pregnancy is a hypercoagulable state, with a 4– to 6-fold increased risk of VTE and a further increase in this risk in the post partum period. Admission of pregnant women to hospital is associated with 18-fold increased VTE risk that is sustained after discharge, especially for women older than 35 years, in the third trimester of pregnancy, and admitted for 3 days or longer. The RCOG guideline recommends that thromboprophylaxis with LMWH is offered to pregnant women when admitted to hospital, unless there is a specific contraindication.

The risk of bleeding from the use of LMWH for thromboprophylaxis is small. In a systematic review, the risk of bleeding in obstetrics and prophylactic LMWH was <2%. Currently, there does not appear to be an increase in bleeding risk with COVID-19 coagulopathy, though caution may be warranted in presence of hypofibrinogenemia, where fibrinogen replacement may be prudent. If bleeding occurs, treatment should follow the principles of sepsis-related coagulopathy and coagulopathy associated with PPH.

6 | KNOWLEDGE/RESEARCH GAPS AND THE ISTH INTERNATIONAL REGISTRY

COVID-19 is a new and evolving disease. The literature addressing the issues of coagulopathy and thrombosis in pregnancy in
association with COVID-19 is sparse and so far, there is no available high-quality evidence to support patients’ care. It is our hope that the recommendations provided here, based on expert opinion, will be of value to those providing care to pregnant women. However, the rapidly evolving nature and the magnitude of the pandemic have led to an acceleration in global research and new publications are emerging on a daily basis. As better evidence accumulates on these aspects of care in pregnancy, an update will be provided.

In order to facilitate the accumulation of knowledge in this area, the ISTH Subcommittee for Women’s Health Issues in Thrombosis and Hemostasis has established an international registry to address issues specifically relevant to pregnancy in the setting of COVID-19 and associated coagulopathy and thrombosis with the potential to close some of the current gaps. The goals of this registry are to gather data on the occurrence of coagulopathies in COVID-19–affected pregnancies in order to examine the link between hemostatic derangements and disease severity; to evaluate the risk and nature of thrombosis; to assess the use, effects, and complications of anticoagulant therapies; and to explore the effects of COVID-19–related coagulopathy and its treatment on maternal and fetal/neonatal outcomes. The registry (https://redcap.isth.org/surveys/?s=4JPX9W98RH) is now available on the ISTH academy website (https://academy.isth.org/isth). Additionally, the project details are available on the ISTH SSC website (https://www.isth.org/members/group.aspx?id=100375). We invite the international scientific community to participate to help advance knowledge and support patient care.

ACKNOWLEDGMENTS
We thank Dr Emmanuel Favaloro for providing editorial feedback to the presubmitted draft.

CONFLICTS OF INTEREST
All authors have no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
RAK, TK, TI, OE, JT, SK, AKM, and MO developed the concept, contributed to the interpretation of data, and provided intellectual input and recommendations. RAK and MO drafted the manuscript. SK conducted the structured literature search, gathered relevant studies, and conducted the quality assessment. MO and AKM designed the registry and data collection tool, which was reviewed and approved by all authors. The ISTH Subcommittee for Women’s Health Issues in Thrombosis and Hemostasis critically reviewed the manuscript and the recommendations and approved the recommendations and the registry.

ORCID
Toshiaki Iba https://orcid.org/0000-0002-0255-4088
Sajida Kazi https://orcid.org/0000-0002-1961-2555
Ann Kinga Malinowski https://orcid.org/0000-0002-3466-7570
Maha Othman https://orcid.org/0000-0001-7562-203X

REFERENCES
1. Johns Hopkins University & Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020. https://coronavirus.jhu.edu/map.html. Accessed on: 21 July 2020
2. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12:194.
3. Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;27:89-94.
4. Knight Marian, Bunch Kathryn, Vousden Nicola, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ. 2020;m2107.
5. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EclinicalMedicine. 2020.25 100446.
6. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020;2(2):1100118.
7. Chen L, Li Q, Zheng D, et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N Engl J Med. 2020;382(25):e100.
8. Vlachodimitropoulou Koumoutsea E, Vivanti AJ, Shehata N, et al. COVID19 and acute coagulopathy in pregnancy. J Thromb Haemost. 2020;18(7):1648-1652.
9. Di Renzo GC, Giardina I. Coronavirus disease 2019 in pregnancy: consider thromboembolic disorders and thrombophylaxis. Am J Obstet Gynecol. 2020;223(1):135.
10. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to COVID-19 disease. Am J Obstet Gynecol. 2020;223(1):109.e1-109.e16.
11. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed: 15 May 2020.
12. Dashraath P, Jing Lin Jeslyn W, Mei Xian Karen L, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020.222(6):521–531.
13. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020;144(7):799-805.
14. Zaighum M, Andersson O. Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies. Acta Obstet Gynecol Scand. 2020;99(7):823-829.
15. Lam CM, Wong SF, Leung TN, et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG. 2004;111:771-774.
16. Mullins E, Evans D, Viner RM, O’Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound Obstet Gynecol. 2020.55(5):586–592.
17. Blitz MJ, Grunebaum A, Tekbali A, et al. Intensive care unit admissions for pregnant and non-pregnant women with COVID-19. Am J Obstet Gynecol. 2020.223(2):290–291.
18. Ellington S, Strid P, Tong VT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection
by pregnancy status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:769-775.

19. Pierce-Williams RM, Burd J, Felder L, et al. Clinical course of severe and critical COVID-19 in hospitalized pregnancies; a US cohort study. Am J Obstet Gynecol MFM. 2020;100134.2(3):100134.

20. Dong L, Tian J, He S, et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. JAMA. 2020;323(18):1846–1848.

21. Zeng H, Xu C, Fan J, et al. Antibodies in infants born to mothers with COVID-19 pneumonia. JAMA. 2020;323(18):1848–1849.

22. Kirtsman M, Diambomba Y, Poutanen SM, et al. Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. Can Med Assoc J. 2020;192(24):E647-E650.

23. Thachil J. The elusive diagnosis of disseminated intravascular coagulation: does a diagnosis of DIC exist anymore? Semin Thromb Hemost. 2019;45:100-107.

24. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-e440.

25. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.

26. Syrropoulos AC, Levy JH, Ageno W, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865.

27. Martinelli I, Ferrazzi E, Ciavarella A, et al. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:1392-1398.

28. Ahmed I, Azhar A, Eltaweel N, Tan BK. First COVID-19 maternal mortality in the UK associated with thrombotic complications. Br J Haematol. 2020;190:e37-e38.

29. Mohammadi S, Abouzaripour M, Hesam Shariati N, Hesam Shariati A, Del Prato S. COVID-19 in people with diabetes: understanding the implications. Diabetes Care. 2020. 46(11):e93240.

30. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus infection. BMJ. Is blood transfusion necessary in all patients with disseminated intravascular coagulopathy associated postpartum hemorrhage? J Matern Fetal Neonatal Med. 2019;32:1004-1008.

31. Levi M, Hunt BJ. Thrombosis and coagulopathy in COVID-19: An illustrated review. Res Pract Thromb Haemost. 2020. 4(5):744-751.

32. COVID-19 Subcommittee of the American Venous Forum. Considerations in prophylaxis and treatment of VTE in COVID-19 patients. https://www.veinforum.org/wp-content/uploads/2020/04/COVID-19-White-Paper-04-17-2020-FINAL-1.pdf. Accessed: 19 May 2020.

33. Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top Guideline No. 37a. 2015. https://www.rcog.org.uk/globalassets/documents/guidelines/gttg-37a.pdf. Accessed: 17 April 2020.

34. Dargaud Y, Rugeri L, Ninet J, Negrier C, Trzeciak MC. Management of pregnant women with increased risk of venous thrombosis. Int J Gynaecol Obstet. 2005;90:203-207.

35. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697-706.

36. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-407.

37. Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013. https://doi.org/10.1111/j.1742-481X.2013.06125.x. [online ahead of print]

38. The American College of Obstetricians and Gynecologists. ACOG practice bulletin number 207: thrombocytopenia in pregnancy. Obstet Gynecol. 2019;133:e181-e193.
58. Qiancheng X, Jia S, Lingling P, et al. Coronavirus disease 2019 in pregnancy. Int J Infect Dis. 2020;95:376-383.

59. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: a report based on 116 cases. Am J Obstet Gynecol. 2020;223(1):111.e1-111.e14.

60. Collin J, Byström E, Carnahan A, Ahrine M, Pregnant and postpartum women with SARS-CoV-2 infection in intensive care in Sweden. Acta Obstet Gynecol Scand. 2020;99(7):819-822.

61. Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, Perez-Medina T. Clinical course of coronavirus disease-2019 in pregnancy. Acta Obstet Gynecol Scand. 2020;99:839-847.

62. Sentilhes L, De Marcillac F, Jouffrieau C, et al. COVID-19 in pregnancy was associated with maternal morbidity and preterm birth. Am J Obstet Gynecol. 2020.5002-9378(20):30639-6.

63. Nayak AH, Kapote DS, Fonseca M, et al. Impact of the coronavirus infection in pregnancy: a preliminary study of 141 patients. J Obstet Gynecol India. 2020;70(4):256-261.

64. Klok FA, Kruij M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.

65. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;20040345.18(8):1995–2002.

66. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.

67. Fogarty H, Townsend L, Ni Cheallagh C, et al. COVID-19 coagulopathy in caucasian patients. Br J Haematol. 2020.189(6):1044–1049.

68. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738-1742.

69. Litijos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-1746.

70. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421-1424.

71. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.

72. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747-1751.

73. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020;142(2):184-186.

74. Spiezia L, Boscolo A, Poletto F, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(06):998-1000.

75. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14.

76. Stoneham SM, Mline KM, Nuttall E, et al. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med. 2020;20:e76-e81.

77. Longchamp A, Longchamp J, Manzocchi-Besson S, et al. Venous thromboembolism in critically ill patients with COVID-19: results of a screening study for deep vein thrombosis. Res Pract Thromb Haemost. 2020;4:842-847.

78. Ren B, Yan F, Deng Z, et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. Circulation. 2020;142:181-183.

79. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection. Blood. 2020.136(4):489–500.

80. Huppensteil JA, Burnham EL, Jolley SE. Prevalence of venous thromboembolism in critically ill patients with COVID-19. Br J Haematol. 2020.190(3):e134–e137.

81. Fraisse M, Logre E, Pajot O, Mentec H, Planteve G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care. 2020;24:275.

82. Santoliquido A, Porfida A, Nesci A, et al. Incidence of deep vein thrombosis among non-ICU Patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14992.

83. Rieder M, Goller I, Jeserich M, et al. Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19. J Thromb Thrombolyis. 2020.1-9.

84. Pavoni V, Giansello L, Pazzi M, Stera C, Meconi T, Frigieri FC. Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia. J Thromb Thrombolysis. 2020:50:281-286.

85. Nougier C, Benoit R, Simon M, et al. Hypofibrinolytic state and high thrombin generation may play a major role in sars-cov-2 associated thrombosis. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.15016. [online ahead of print]

86. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.

87. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.

88. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145-148.

89. Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020;92(9):1533-1541.

90. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.

91. Klok FA, Kruij M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;19:148-150.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.